Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Fig 2
Survival estimates at 2 years according to key patient criteria among axial flow LVAD recipients enrolled in INTERMACS between 2010–2015.
N shows number of patients in each sub-group. Points in the plot shows survival probability at 2y; error bars show 95% CI. Numerical estimate and 95% CI are shown with Log-rank test p-value.